Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

156.16

-0.20

(-0.13%)

As of 03:41PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Triple Moving Average Crossover

View all chart patterns

Performance Outlook

Previous Close	156.36
Open	154.02
Bid	156.00 x 1000
Ask	156.10 x 800
Day's Range	154.00 - 157.56
52 Week Range	117.64 - 186.22
Volume	290,838
Avg. Volume	559,980

Market Cap	9.751B
Beta (5Y Monthly)	0.80
PE Ratio (TTM)	N/A
EPS (TTM)	-7.37
Earnings Date	May 04, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	201.65

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for JAZZ

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Jazz Pharmaceuticals plc
JAZZ: Raising target price to $171.00JAZZ PHARMACEUTICALS PLC has an Investment Rating of BUY; a target price of $171.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
Rating
Fair Value
Economic Moat
yesterdayArgus Research

All

Benzinga
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed. Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) struggled to differentiate Sunosi in a generic market, and SVB remains skeptical that Axsome will be able to do much better. Related: Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its
Investor's Business Daily
IBD 50 Stocks To Watch: This Pharma Stock Rides Health Care Wave
Jazz Pharmaceuticals stands out in the IBD 50 as it rides the wave of the health care sector on concerns of a looming recession.
- Stock Market Bounces But IBD 50, Small Caps Lag; This Stock Takes A Bath
  Investor's Business Daily
- Is AFRM A Buy Now Or A Sell? What Affirm's Fundamentals, IBD Ratings, Stock Chart Say
  Investor's Business Daily
Zacks
JAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols Fails
JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.